Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (191-200 of 662) with videos related to

Pageof 67
Sort By:
The Journal of Allergy and Clinical Immunology|April 25, 2007
Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significanceAlexandra Böhm, Manuela Födinger, Friedrich Wimazal, et al.
Expert Review of Hematology|August 30, 2014
The serum tryptase test: an emerging robust biomarker in clinical hematologyPeter Valent, Wolfgang R Sperr, Karl Sotlar, et al.
Leukemia & Lymphoma|December 3, 2005
Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignanciesStefan Florian, Karoline Sonneck, Alexander W Hauswirth, et al.
Leukemia Research|May 4, 2004
Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotypePeter Valent, Christa Fonatsch, Reinhard Stindl, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 24, 2002
Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergyInes Swoboda, Agnes Bugajska-Schretter, Petra Verdino, et al.
Leukemia Research|May 18, 2007
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interfaceFriedrich Wimazal, Christa Fonatsch, Renate Thalhammer, et al.
Leukemia Research|May 27, 2017
Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CMLPeter Valent, Emir Hadzijusufovic, Gregor Hoermann, et al.
Molecular Oncology|April 23, 2009
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemiaOliver Hantschel, Agnes Gstoettenbauer, Jacques Colinge, et al.
Leukemia Research|September 17, 2011
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDSPeter Valent, Barbara J Bain, John M Bennett, et al.
Annals of Hematology|March 24, 2018
Major response of PNH to an AML chemotherapy protocolWolfgang Füreder, Wolfgang R Sperr, Karoline Gleixner, et al.
Pageof 67

Showing results (191-200 of 662) with videos related to

Sort By:
Pageof 67
The Journal of Allergy and Clinical Immunology|April 25, 2007
Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significanceAlexandra Böhm, Manuela Födinger, Friedrich Wimazal, et al.
Expert Review of Hematology|August 30, 2014
The serum tryptase test: an emerging robust biomarker in clinical hematologyPeter Valent, Wolfgang R Sperr, Karl Sotlar, et al.
Leukemia & Lymphoma|December 3, 2005
Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignanciesStefan Florian, Karoline Sonneck, Alexander W Hauswirth, et al.
Leukemia Research|May 4, 2004
Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotypePeter Valent, Christa Fonatsch, Reinhard Stindl, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 24, 2002
Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergyInes Swoboda, Agnes Bugajska-Schretter, Petra Verdino, et al.
Leukemia Research|May 18, 2007
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interfaceFriedrich Wimazal, Christa Fonatsch, Renate Thalhammer, et al.
Leukemia Research|May 27, 2017
Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CMLPeter Valent, Emir Hadzijusufovic, Gregor Hoermann, et al.
Molecular Oncology|April 23, 2009
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemiaOliver Hantschel, Agnes Gstoettenbauer, Jacques Colinge, et al.
Leukemia Research|September 17, 2011
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDSPeter Valent, Barbara J Bain, John M Bennett, et al.
Annals of Hematology|March 24, 2018
Major response of PNH to an AML chemotherapy protocolWolfgang Füreder, Wolfgang R Sperr, Karoline Gleixner, et al.
Pageof 67